DTB Editorial: Making medicines safer?

In the context of an accelerated licensing route outlined in the MHRA business plan for 2021, this editorial highlights that safety and well-being of pts must be paramount in all decisions about licensing of medicines and pts must be put at the centre of any new licensing process


Drug and Therapeutics Bulletin